{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:41:59Z","timestamp":1780339319387,"version":"3.54.1"},"reference-count":61,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UNDP\/World Bank\/WHO Special Program for Research and Training in Tropical Diseases","award":["A00790"],"award-info":[{"award-number":["A00790"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>The therapeutic management of Chagas disease requires new medicines because the standard-of-care drugs available induce adverse effects and have limited efficacy. In this study, we developed a formulation of albaconazole (ABZ) loaded in biodegradable polymeric nanocapsules (NCs). Free ABZ and ABZ-loaded NCs were similarly active against the Y strain and inactive against the Colombian strain epimastigotes of Trypanosoma cruzi. Infected mice were given ABZ in different doses and treatment schedules by oral, SC, and IM routes during the acute phase of infection. Free ABZ taken orally reduced parasitemia and suppressed mortality; however, all the animals maintained patent parasitemia during and after treatment. ABZ-NCs increased anti-T. cruzi effects (p &lt; 0.05), inducing negative parasitemia during treatment in most of the tested regimens. The parasitemia level was also significantly reduced after treatment with ABZ-NCs during the acute phase of the disease, and relapses were delayed compared with the free ABZ treatment. Once- and twice-daily doses were similarly effective, demonstrating that the NCs prolonged the ABZ-NC residence time. Free ABZ and ABZ-NCs did not prevent infection, ABZ seemed to have suppressive effects on T. cruzi growth, and encapsulation prolonged this suppression. The analysis of the in vivo results indicated that the NCs significantly improved the safety of ABZ in the mouse model, suggesting that the increased ABZ-NC dosage regimen merits further efficacy and pharmacokinetic evaluations.<\/jats:p>","DOI":"10.3390\/pathogens14040319","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T06:58:43Z","timestamp":1742972323000},"page":"319","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Albaconazole Polymeric Nanocapsules for Treating Trypanosoma cruzi Infections"],"prefix":"10.3390","volume":"14","author":[{"given":"Cristina Maria","family":"de Barros","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutics and Nanotechnology, School of Pharmacy, Federal University of Ouro Preto, Campus Universit\u00e1rio Morro do Cruzeiro, Ouro Preto 35400-000, MG, Brazil"},{"name":"Post-Graduation Program in Biological Sciences (NUPEB), Exact and Biological Sciences Institute (ICEB), Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja Maria","family":"Veloso","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth Spangler","family":"Andrade","sequence":"additional","affiliation":[{"name":"Laboratory of Nanoscopy, FIEMG SENAI Technological Center\u2014Regional Department of Minas Gerais, Belo Horizonte 31035-536, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M\u00e1rio Carneiro","family":"Vilela","sequence":"additional","affiliation":[{"name":"Laboratory of Nanoscopy, FIEMG SENAI Technological Center\u2014Regional Department of Minas Gerais, Belo Horizonte 31035-536, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics and Nanotechnology, School of Pharmacy, Federal University of Ouro Preto, Campus Universit\u00e1rio Morro do Cruzeiro, Ouro Preto 35400-000, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1565-4707","authenticated-orcid":false,"given":"Marta","family":"de Lana","sequence":"additional","affiliation":[{"name":"Post-Graduation Program in Biological Sciences (NUPEB), Exact and Biological Sciences Institute (ICEB), Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil"},{"name":"Department of Clinical Analysis, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Terezinha","family":"Bahia","sequence":"additional","affiliation":[{"name":"Post-Graduation Program in Biological Sciences (NUPEB), Exact and Biological Sciences Institute (ICEB), Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil"},{"name":"Parasitic Diseases Laboratory, School of Medicine, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-6090","authenticated-orcid":false,"given":"Vanessa Carla Furtado","family":"Mosqueira","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics and Nanotechnology, School of Pharmacy, Federal University of Ouro Preto, Campus Universit\u00e1rio Morro do Cruzeiro, Ouro Preto 35400-000, MG, Brazil"},{"name":"Post-Graduation Program in Biological Sciences (NUPEB), Exact and Biological Sciences Institute (ICEB), Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil"},{"name":"Department of Pharmacy, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"ref_1","unstructured":"PAHO\/WHO\u2014Pan American Health Organization (2025, January 10). Chagas Disease in the Americas for Public Health Workers-PAHO\/WHO. Available online: https:\/\/www.who.int\/campaigns\/world-chagas-disease-day\/2022."},{"key":"ref_2","unstructured":"PAHO\/WHO (2019). PAHO\/WHO: Guidelines for the Diagnosis and Treatment of Chagas Disease, PAHO\/WHO."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Brindley, P.J., Hotez, P.J., and Kamhawi, S. (2025). Revisiting What Constitutes a Neglected Tropical Disease?. PLoS Negl. Trop. Dis., 19.","DOI":"10.1371\/journal.pntd.0012794"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/13543784.2024.2349289","article-title":"Drugs in Preclinical and Early Clinical Development for the Treatment of Chagas\u2019s Disease: The Current Status","volume":"33","author":"Torchelsen","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1590\/S0036-46652002000100006","article-title":"Long term evaluation of etiological treatment of chagas disease with benznidazole","volume":"44","year":"2002","journal-title":"Rev. Inst. Med. Trop. S\u00e3o Paulo"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4269\/ajtmh.2004.71.594","article-title":"Short report: Benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up","volume":"71","author":"Andrade","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1590\/S0074-02761999000700070","article-title":"Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina","volume":"94","author":"Segura","year":"1999","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yun, O., Lima, M.A., Ellman, T., Chambi, W., Castillo, S., Flevaud, L., Roddy, P., Parreno, F., Albajar, V.P., and Palma, P.P. (2009). Feasibility, drug safety, and effectiveness of etiological treatment programs for chagas disease in honduras, guatemala, and bolivia: 10-year experience of medecins sans frontieres. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000488"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0002-8703(94)90521-5","article-title":"Treatment of chronic Chagas disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up","volume":"127","author":"Viotti","year":"1994","journal-title":"Am. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1574891X11666161024165304","article-title":"Targets and patented drugs for chemotherapy of Chagas disease in the last 15 years-period","volume":"11","author":"Duschak","year":"2016","journal-title":"Recent Pat. Anti-Infect. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijpddr.2011.12.002","article-title":"Recent developments in sterol 14-demethylase inhibitors for Chagas disease","volume":"2","author":"Buckner","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/jm9707277","article-title":"New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones","volume":"41","author":"Turmo","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_13","first-page":"529","article-title":"Casta\u00f1er","volume":"28","author":"Sorbera","year":"2003","journal-title":"Drugs Future"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lion, T. (2017). Systemic Antifungal Agents: Current Status and Projected Future Developments. Human Fungal Pathogen Identification, Humana Press. Methods in Molecular Biology.","DOI":"10.1007\/978-1-4939-6515-1"},{"key":"ref_15","first-page":"88","article-title":"Overview of albaconazole","volume":"5","author":"Bartroli","year":"2011","journal-title":"Eur. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1021\/ml300429p","article-title":"Discovery of a Novel Broad-Spectrum Antifungal Agent Derived from Albaconazole","volume":"4","author":"Guillon","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cpdd.72","article-title":"A randomized, double-blind, multiple-dose, placebo-controlled, dose escalation study with a 3-cohort parallel group design to investigate the tolerability and pharmacokinetics of albaconazole in healthy subjects","volume":"3","author":"Dietz","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_18","first-page":"23","article-title":"A Phase I, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation","volume":"5","author":"Lowe","year":"2013","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaad.2013.03.021","article-title":"A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis","volume":"69","author":"Sigurgeirsson","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1128\/AAC.48.2.384-387.2004","article-title":"In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans","volume":"48","author":"Miller","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.45.9.2635-2637.2001","article-title":"In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi","volume":"45","author":"Capilla","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/AAC.44.9.2498-2502.2000","article-title":"In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi","volume":"44","author":"Urbina","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1128\/AAC.48.11.4286-4292.2004","article-title":"Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts","volume":"48","author":"Guedes","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/13543780903176407","article-title":"New generation azole antifungals in clinical investigation","volume":"18","author":"Girmenia","year":"2009","journal-title":"Exp. Opin. Investig. Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/13543784.15.6.579","article-title":"Newer triazole antifungal agents: Pharmacology, spectrum, clinical efficacy and limitations","volume":"15","author":"Aperis","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_26","first-page":"165","article-title":"Novel triazole antifungal drugs: Focus on isavuconazole, ravuconazole and albaconazole","volume":"11","author":"Pasqualotto","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/09546634.2020.1729336","article-title":"Oral antifungal therapies for toenail onychomycosis: A systematic review with network meta-analysis toenail mycosis: Network meta-analysis","volume":"33","author":"Bonetti","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_28","unstructured":"Bartroli, X., and Uriach, J. (2005, January 16\u201319). A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: Abs M-722, Washington, DC, USA."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4155\/cli.11.137","article-title":"New-generation triazole antifungal drugs: Review of the Phase II and III trials","volume":"1","author":"Girmenia","year":"2011","journal-title":"Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Branquinho, R.T., Roy, J., Farah, C., Garcia, G.M., Aimond, F., Le Guennec, J.-Y., Saude-Guimar\u00e3es, D.A., Grabe-Guimaraes, A., Mosqueira, V.C.F., and de Lana, M. (2017). Biodegradable Polymeric Nanocapsules Prevent Cardiotoxicity of Anti-Trypanosomal Lychnopholide. Sci. Rep., 7.","DOI":"10.1038\/srep44998"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Branquinho, R.T., Pound-Lana, G., Marques Milagre, M., Sa\u00fade-Guimar\u00e3es, D.A., Vilela, J.M.C., Spangler Andrade, M., de Lana, M., and Mosqueira, V.C.F. (2017). Increased Body Exposure to New Anti-Trypanosomal Through Nanoencapsulation. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-08469-x"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01937-19","article-title":"Lychnopholide in Poly(d,l-Lactide)- block -Polyethylene Glycol Nanocapsules Cures Infection with a Drug-Resistant Trypanosoma cruzi Strain at Acute and Chronic Phases","volume":"64","author":"Branquinho","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","unstructured":"Formiga, F.R., and Severino, P. (2021). Chapter 9\u2014Nanomedicines against Chagas disease. Applications of Nanobiotechnology for Neglected Tropical Diseases, Academic Press. [1st ed.]."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1007\/s00436-022-07618-0","article-title":"In vitro interaction of polyethylene glycol-block-poly(D,L-lactide) nanocapsule devices with host cardiomyoblasts and Trypanosoma cruzi-infective forms","volume":"121","author":"Siqueira","year":"2022","journal-title":"Parasitol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1253\/circj.71.1323","article-title":"Frequent premature ventricular contractions induced by itraconazole","volume":"71","author":"Okamoto","year":"2007","journal-title":"Circ. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1399-3062.2006.00160.x","article-title":"Torsades de pointes associated with voriconazole use","volume":"9","author":"Philips","year":"2007","journal-title":"Transpl. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1345\/aph.10210","article-title":"Fluconazole-induced torsade de pointes","volume":"35","author":"Tholakanahalli","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.lfs.2006.12.019","article-title":"Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices","volume":"80","author":"Leite","year":"2007","journal-title":"Life Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1111\/bph.15186","article-title":"Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation","volume":"177","author":"Cruz","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/tmi.13899","article-title":"Acute Chagas disease associated with ingestion of contaminated food in Brazilian western Amazon","volume":"28","author":"Ortiz","year":"2023","journal-title":"Trop. Med. Int. Health"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0378-5173(89)90281-0","article-title":"Nanocapsule formation by interfacial polymer deposition following solvent displacement","volume":"55","author":"Fessi","year":"1989","journal-title":"Int. J. Pharm."},{"key":"ref_42","unstructured":"ANVISA, and National Health Surveillance Agency Ministry of Health, BRAZIL (2018, July 20). Resolution RDC n\u00b0 166, of July 24, 2017. Provides Criteria for the Validation of Analytical Methods. Official Gazette of the Federative Republic of Brazil, Bras\u00edlia, DF, Section 1 25 July, Available online: https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2017\/rdc0166_24_07_2017.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/02652049509015290","article-title":"In vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride","volume":"12","author":"Fessi","year":"1995","journal-title":"J. Microencapsul."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1590\/S0074-02762009000700021","article-title":"A New Consensus for Trypanosoma cruzi Intraspecific Nomenclature: Second Revision Meeting Recommends TcI to TcVI","volume":"104","author":"Zingales","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1590\/0074-0276140156","article-title":"Drug discovery for chagas disease should consider Trypanosoma cruzi strain diversity","volume":"109","author":"Zingales","year":"2014","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0035-9203(87)90020-4","article-title":"Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas\u2019 disease","volume":"81","author":"Filardi","year":"1987","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_47","first-page":"89","article-title":"Therapeutic activity and criterion of cure in mice experimentally infected with Trypanosoma cruzi","volume":"4","author":"Brener","year":"1962","journal-title":"Rev. Inst. Med. Trop. S\u00e3o Paulo"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1590\/S0074-02762010000200022","article-title":"In vitro and in vivo experimental models for drug screening and development for Chagas disease","volume":"105","author":"Romanha","year":"2010","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S0037-86821989000100004","article-title":"Hemocultures for the parasitological diagnosis of human chronic Chagas\u2019 disease","volume":"22","author":"Chiari","year":"1989","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1017\/S1431927605050865","article-title":"Poly-Caprolactone Nanocapsules Morphological Features by Atomic Force Microscopy","volume":"11","author":"Leite","year":"2005","journal-title":"Microsc. Microanal."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1590\/S0074-02762001000700021","article-title":"Variation in Susceptibility to Benznidazole in Isolates Derived from Trypanosoma cruzi Parental Strains","volume":"96","author":"Veloso","year":"2001","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1021\/jm4016284","article-title":"Design, Synthesis, and Structure-Activity Relationship Studies of Novel Fused Heterocycles-Linked Triazoles with Good Activity and Water Solubility","volume":"57","author":"Cao","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"E1224 Study Group. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","unstructured":"Bartroli, J., Turmo, E., Alguer\u00f3, M., Boncompte, E., Vericat, M.L., Conte, L., Ramis, J., Garc\u00eda-Rafanell, J., and Forn, J. (2018, July 20). UR-9825: A New Triazole Derivative with Potent, Broad-Spectrum Antifungal Activity. Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 1997, abstr. E-67, September, Toronto, Canada. American Soc. for Microbiology, Washington, DC. Available online: https:\/\/search.worldcat.org\/pt\/title\/633698851."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejps.2018.08.024","article-title":"Mechanisms of interaction of biodegradable polyester nanocapsules with non-phagocytic cells","volume":"124","author":"Trindade","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chen, C.K., Leung, S.S., Guilbert, C., Jacobson, M.P., McKerrow, J.H., and Podust, L.M. (2010). Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000651"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e60226","DOI":"10.7554\/eLife.60226","article-title":"Glutamine metabolism modulates azole susceptibility in Trypanosoma cruzi amastigotes","volume":"9","author":"Dumoulin","year":"2020","journal-title":"eLife"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1017\/S0031182017002207","article-title":"Reduced cardiotoxicity and increased oral efficacy of artemether polymeric nanocapsules in Plasmodium berghei-infected mice","volume":"145","author":"Souza","year":"2018","journal-title":"Parasitology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/AAC.48.4.1222-1228.2004","article-title":"Efficacy and Pharmacokinetics of Intravenous Nanocapsule Formulations of Halofantrine in Plasmodium berghei-Infected Mice","volume":"48","author":"Mosqueira","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1166\/jnn.2006.444","article-title":"Surface-Modified and Conventional Nanocapsules as Novel Formulations for Parenteral Delivery of Halofantrine","volume":"6","author":"Mosqueira","year":"2006","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0020-7519(01)00158-8","article-title":"Parasite persistence in the aetiology of Chagas disease","volume":"31","author":"Tarlenton","year":"2001","journal-title":"Int. J. Parasitol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/4\/319\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:00:36Z","timestamp":1760029236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/4\/319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["pathogens14040319"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14040319","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}